Benzinga | Nov 15, 2021 11:06AM EST

Chembio Diagnostics Announces Extension Of Delivery Schedule For Bio Manguinhos Purchase Order Of DPP SARS-COV-2 Antigen Tests

Chembio Diagnostics, Inc. ("Chembio") (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that the delivery schedule for shipments of DPP SARS-COV-2 Antigen Tests under its July 2021 purchase order from Bio Manguinhos has been extended into March 2021. As the result of a portion of the shipments now being deliverable after year end, Chembio believes it now has the opportunity to fulfill all of the $28.3 million order. Chembio's delivery of tests covered by the purchase order, however, continues to be negatively affected by limitations of Chembio's supply chain, staffing, and liquidity, and other matters outside Chembio's control.



"Bio-Manguinhos is a valued long-time customer, and we appreciate their collaboration as we strive to meet their needs during the COVID-19 pandemic," said Richard Eberly, Chembio's President and Chief Executive Officer. "Our team continues to maximize the use of our resources to efficiently increase production capacity. We are focused on making continued improvements to scale the business for future growth."

The DPP SARS-CoV-2 Antigen test is designed to detect the SARS-CoV-2 antigen, which indicates an active COVID-19 infection, in only 20 minutes using a minimally invasive nasal swab.